Cardiac Events After Osimertinib Treatment in Lung Cancer
Author Information
Author(s): Le Jonathan N., Gasho Jordan O., Peony Olivia, Singh Asneh, Silos Katrina D., Kim Sungjin, Nguyen Anthony T., Kamrava Mitchell, Mirhadi Amin, Hakimian Behrooz, Reckamp Karen L., Sankar Kamya, Mak Raymond H., Nikolova Andriana P., Atkins Katelyn M.
Primary Institution: Cedar-Sinai Medical Center, Los Angeles, CA, United States
Hypothesis
What are the cardiac effects of osimertinib treatment in lung cancer patients?
Conclusion
Osimertinib treatment is associated with significant cardiac events, including QTc prolongation and reduced left ventricular ejection fraction.
Supporting Evidence
- 19.2% of patients experienced grade ≥2 cardiac events within 2 years.
- QTc was prolonged from 437 ms to 451 ms after treatment.
- 10.6% of patients had LVEF ≤50% post-treatment compared to 5.3% at baseline.
- Pre-existing arrhythmia increased the risk of cardiac events by 3.9 times.
- Higher body mass index was associated with increased risk of cardiac toxicity.
Takeaway
This study found that many lung cancer patients treated with osimertinib experienced heart problems, like a longer heartbeat and weaker heart function.
Methodology
Retrospective analysis of NSCLC patients treated with osimertinib and monitored with echocardiograms and ECGs.
Potential Biases
Potential selection bias as the cohort may represent higher cardiovascular risk patients.
Limitations
The study is retrospective and may not fully capture the incidence of cardiac dysfunction due to selection bias and variable monitoring practices.
Participant Demographics
Mean age 68 years, 67% female, 64.7% white, 15.3% Hispanic/Latin(x).
Statistical Information
P-Value
0.034
Confidence Interval
95% CI: 1.11–13.72
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website